Detailed Workflow of Immunopeptidomics Analysis Based on LC-MS/MS

With immunotherapy becoming a research hotspot for intervention in tumors, viral infections, and autoimmune diseases, our understanding of antigen presentation mechanisms continues to deepen. In this context, immunopeptidomics has emerged as a crucial bridge connecting molecular genomics and immunology. This technology aims to comprehensively identify the peptide assemblies presented to the cell surface by major histocompatibility complex (MHC) molecules, which can be directly recognized by T cells and trigger an immune response. Therefore, immunopeptidomics not only holds broad prospects for the development of new vaccines but also provides reliable antigen screening for individualized cancer immunotherapy. LC-MS/MS-based immunopeptidomics analysis technology can directly detect peptides presented by MHC molecules in real biological samples, making it the most direct and reliable technological path for studying antigen presentation mechanisms. This article systematically outlines the LC-MS/MS-based immunopeptidomics analysis process, from sample preparation to mass spectrometry detection and data analysis, to help researchers understand the key points and application value of this cutting-edge technology.

 

I. Basic Principles and Research Subjects of Immunopeptidomics

The research subjects of immunopeptidomics are endogenous peptides presented by MHC-I or MHC-II molecules. These peptides originate from the degradation products of intracellular proteins, reflecting the molecular state of the cell, including cancerous changes, infections, or stress. MHC-I mainly presents short peptides of 8–11 amino acids from within the cell to activate CD8+ T cells, while MHC-II is responsible for presenting longer peptides (13–25 amino acids) to activate CD4+ T cells.

Research focuses typically include:

• Tumor-associated antigens (TAA)
• Tumor-specific neoantigens
• Pathogen-derived antigens (such as viruses, bacteria)
• Autoantigens (related to autoimmune diseases)

These peptides are the core basis for developing personalized vaccines, TCR-T therapy, and targeted treatment strategies.

 

II. Complete Experimental Workflow of LC-MS/MS-Based Immunopeptidomics

The biggest challenge in immunopeptidomics experiments is the low abundance and high complexity of target peptides. Therefore, experimental design must be highly optimized to improve detection sensitivity and data quality.

1. Sample Preparation

Common samples include cancer cell lines, patient tumor tissues, PBMC, HLA-transfected cells, etc. Due to the scarcity of peptides presented by MHC, an enormous number of cells or equivalent tissue amounts are usually required to reach detectable levels of immunopeptides.

 

2. Immunoprecipitation (IP) of MHC Molecules

Specific antibodies (such as W6/32 for HLA-I) coupled with magnetic beads or agarose gel are used for immunoprecipitation to enrich MHC-peptide complexes. The key to this step is the integrity of sample lysis and the binding efficiency of the antibody, directly affecting the purity and recovery rate of downstream peptides.

 

3. Weak Acid Elution of Peptides

Peptides bound to MHC are eluted using weak acid conditions such as 0.1% TFA. The elution solution contains a large amount of background substances, so rapid, low-temperature operations are required to prevent protein degradation and maximize retention of target peptides.

 

4. Peptide Purification and Concentration

The elution solution is purified using C18 solid-phase extraction columns to remove salts, surfactants, and other interfering substances. If necessary, high-pH reverse-phase fractionation can further enhance the detection probability of low-abundance peptides.

 

5. LC-MS/MS Analysis

High-resolution mass spectrometry platforms (such as Orbitrap Exploris, Fusion Lumos) are used for full-scan analysis under non-enzymatic settings. Data acquisition mode is typically DDA (Data-Dependent Acquisition), although DIA (Data-Independent Acquisition) can be used to increase coverage.

Recommended parameter settings include:

(1) Dynamic exclusion to avoid redundant scanning;

(2) Longer chromatographic gradients to enhance separation;

(3) Higher AGC and resolution to increase sensitivity.

 

6. Data Analysis and Antigen Screening

Data analysis requires algorithms supporting non-enzymatic searches (such as MaxQuant, PEAKS, Byonic) and setting an appropriate false discovery rate (FDR ≤ 1%). Subsequently, peptides are matched to the HLA type information of the target cell or tissue to confirm their MHC restriction. Combining somatic mutation data and transcriptome data, immunogenic neoantigen candidates can be screened.

 

III. Prospects of Immunopeptidomics Applications

As a technology connecting the degradation products of cellular proteins and T cell recognition mechanisms, immunopeptidomics is showing tremendous potential in multiple research and application fields:

1. Personalized Tumor Vaccine Design:By identifying patient-specific neoantigens, improving T cell activation efficiency;

2. TCR-T or CAR-T Target Discovery:Confirming antigens with strong expression specificity and high immunogenicity;

3. Virus or Pathogen Vaccine Development:For example, screening specific antigens of COVID-19 variants;

4. Autoimmune Disease Mechanism Research:Identifying autoantigenic peptides that potentially induce self-reactivity.

With the continuous improvement of mass spectrometry technology, algorithm capabilities, and multi-omics integration methods, immunopeptidomics will play an increasingly critical role in the field of precision immunotherapy.

 

Immunopeptidomics, with its high physiological relevance and technological foresight, is reshaping our understanding of antigen recognition and immune response. The direct peptide identification method based on LC-MS/MS has become a crucial support platform for neoantigen discovery and individualized immunotherapy development. In the future, with ongoing optimization of sample processing efficiency and algorithm precision, immunopeptidomics is expected to bring more breakthroughs to precision medicine. For customized immunopeptidomics research strategies, please contact Biotyper Biotech for technical consultation and solution support.

 

High-precision mass spectrometry-based immunopeptidomics analysis and neoantigen discovery